NCT06098898 2023-10-25
Safety and Efficacy of NK510 to Treat Gastric Cancer
Base Therapeutics (Shanghai) Co., Ltd.
Phase EARLY_PHASE1 Unknown
Clinical Trials
23 trialsNCT04591431 2023-10-03
ROME
Fondazione per la Medicina Personalizzata
Phase 2 Unknown
NCT04819971 2023-04-25
Study of Perioperative Chemotherapy Combined With Tislelizumab and Trastuzumab in the Treatment of GC/EGC
The First Affiliated Hospital of Zhengzhou University
Phase 2 Unknown
NCT05170256 2022-08-12
HERES
Rigshospitalet, Denmark
Phase 2 Unknown
NCT05218148 2022-04-06
SOX Combined With Sintilimab and Trastuzumab Versus SOX Regimen in the Perioperative Treatment of HER2-positive Locally Advanced Gastric Adenocarcinoma
ChineseAMS
Phase 2 Unknown
NCT05311189 2022-04-05
Study of HLX10, Trastuzumab and Chemotherapy in First-line Treatment of HER2-positive Recurrent/Metastatic Gastric Cancer
Shanghai Zhongshan Hospital
Phase 2 Unknown
NCT03457896 2022-03-31
Study of Neratinib +Trastuzumab or Neratinib + Cetuximab in Patients With KRAS/NRAS/BRAF/PIK3CA Wild-Type Metastatic Colorectal Cancer by HER2 Status
NSABP Foundation Inc
Phase 2 Unknown
NCT05193292 2022-01-14
Camrelizumab Combined With Trastuzumab and Chemotherapy in Patients With HER2-positive Advanced Colorectal Cancer
Fudan University
Phase 2 Unknown
NCT04380012 2021-07-15
A Clinical Study of Pyrotinib in Patients With HER2-positive Advanced Colorectal Cancer
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Unknown
NCT04960943 2021-07-14
Efficacy and Safety of Pyrotinib in HER2 Positive Gastrointestinal Tumors
Fudan University
Phase 2 Unknown
NCT04888663 2021-05-21
Study of Ramucirumab, Trastuzumab and Paclitaxel in Patients With HER2-positive Recurrent/Metastatic Gastric Cancer (HER-RAM Study)
Yonsei University
Phase 1/2 Unknown
NCT02901301 2021-04-06
Pembrolizumab, Trastuzumab, HER2 Positive Gastric Cancer
Yonsei University
Phase 1/2 Unknown
NCT01359397 2021-01-27
B-DOCT
The Netherlands Cancer Institute
Phase 2 Unknown
NCT03185988 2019-07-19
Anti-HER2 Therapy in Patients of HER2 Positive Metastatic Carcinoma of Digestive System
Peking University
Phase 2 Unknown
NCT03843749 2019-02-18
Pyrotinib in Combination With Trastuzumab in Treatment-refractory, HER2-positive Metastatic Colorectal Cancar.
Shanghai Changzheng Hospital
Phase NA Unknown
NCT03225937 2018-10-30
HERACLES
Fondazione del Piemonte per l'Oncologia
Phase 2 Unknown
NCT02836847 2018-05-07
Molecularly Target Therapy With GEMOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma
Shanghai Jiao Tong University School of Medicine
Phase 2 Unknown
NCT01228045 2016-06-22
A Study of Trastuzumab in Combination With TS-ONE & Cisplatin in First-line Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer
National University Hospital, Singapore
Phase 2 Unknown
NCT02030561 2016-06-22
NK Cell Infusions With Trastuzumab for Patients With HER2+ Breast and Gastric Cancer
National University Hospital, Singapore
Phase 1/2 Unknown
NCT02805829 2016-06-22
Combination Trastuzumab With Expanded Natural Killer Cells for Treating HER2-positive Gastric Cancer
Xuzhou Medical University
Phase 1/2 Unknown
NCT02380131 2015-03-05
Perioperative Chemotherapy With Herceptin For Potentially Resectable HER-2 Positive Gastric Cancer With Liver Metastasis
Hebei Medical University
Phase 4 Unknown
NCT02250209 2014-09-26
T- XELOX in HER2-positive Stage III Gastric Cancer After D2 Gastrectomy
Chinese PLA General Hospital
Phase 2 Unknown
NCT00003797 2013-12-19
Gemcitabine and Monoclonal Antibody Therapy in Treating Patients With Metastatic Cancer of the Pancreas
National Cancer Institute (NCI)
Phase 2 Unknown